2018/19 Public Policy Initiatives
Examples of 2018/19 Public Policy Initiatives
CSL has offered its expertise to Chinese government stakeholders in exploring solutions to address the unmet needs of rare disease patients in China.
CSL has continued to engage with the biotech sector and the Australian Federal Government in relation to the research and development (R&D) tax incentive. We provided written and oral input to a Senate inquiry specifically opposing proposed changes which would have disadvantaged companies which manufacture in Australia.
CSL Behring is engaging with stakeholders on the European Blood Directive to promote an environment for efficient and safe collection of plasma that meets the need of patients in Europe.
CSL Behring is also collaborating with leading patient organisations such as EURORDIS, European Haemophilia Consortium or Alpha-1 for joint initiatives on improving patient access to rare disease therapies.
To help supply information for policy analysis and discussion, Seqirus sponsored the International Longevity Center (ILC -UK) to conduct, “An economic analysis of flu vaccination”. This report presents findings from a new economic model on cost-benefit analyses for differing uptake and efficacy scenarios for the English flu vaccination programme. Given the rapidly ageing population of the UK and growing pressures on the National Health Service (NHS), tackling influenza is an important challenge, especially during the winter months when flu and other related health conditions are most prevalent. Vaccinations are recognised as a crucial defence against flu outbreaks, helping to protect individuals directly and by creating herd immunity. Key findings include that Vaccination averts between 180,000 and 626,000 cases of influenza per year in England, and that flu vaccination helps avert between 5,678 and 8,800 premature deaths per year.
In North America
CSL Behring has supported the efforts of state haemophilia associations in Arizona and Virginia, US, in addition to the Immune Deficiency Foundation, to secure legislation that restricts co-pay accumulator programs in those states. Co-pay accumulator programs are used by health insurers to track utilization of pharmaceutical manufacturer-sponsored co-payment assistance programs and ensure that the manufacturer contribution does not count toward a patient’s deductible or otherwise reduce the patient’s responsibility for out-of-pocket expenses. Patients whose insurers utilise co-pay accumulator programs are unable to benefit from assistance, and as a result, must pay more directly out of pocket.